Li Min

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Li Min

What is Li Min? Entity Definition and Classification

Property Description
Active Ingredient Cetirizine Hydrochloride
Form Tablet, Oral Solution, Capsule
Pharmacological Class Second-Generation Antihistamine
Common Use Relief of general allergic symptoms
Origin Synthetic, Piperazine derivative

Li Min is the trade name for a medication whose core chemical identity is the synthetic compound, Cetirizine Hydrochloride, which serves as the sole active ingredient. This orally administered compound is classified pharmacologically as a Second-Generation Antihistamine (SGAH). The general therapeutic purpose of this medication is to provide relief from the common signs of allergic reactions, utilizing an oral route of administration.


Classification and Mechanism

Li Min functions as a highly selective H1-receptor antagonist. This classification means the drug works by blocking the action of histamine, the body’s natural chemical mediator that causes most allergy symptoms. Cetirizine Hydrochloride is an effective agent for managing chronic allergic conditions due to its potent, targeted action. Consequently, the medicine is reliable for controlling a range of bothersome allergic signs.


Composition and Antiallergic Action

The medication is a single active ingredient product, distinguishing it from combination treatments. By blocking the binding of histamine to its target receptors, Cetirizine provides consistent, fast-acting control over reactions such as sneezing, itching, and watery eyes. Second-generation antihistamines are designed to minimize the potential for sedation compared to older compounds. As a result, patients can generally expect relief from allergic symptoms with minimal impact on their daily cognitive function. The substance is made available in several dosage forms, including the standard tablet, capsule, and liquid oral solution, to suit different patient needs.

Regulatory References

  1. Cetirizine: MedlinePlus Drug Information
  2. Cetirizine - StatPearls - NIH
  3. Antihistamines - StatPearls - NIH

What side effects are possible with Li Min?

Possible Side Effects and Safety Information

The safety profile of Li Min (Cetirizine Hydrochloride) is formally categorized by frequency tiers established in regulatory documentation, such as those from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Reactions are grouped by System-Organ Class (SOC) to define the scope of potential effects.


Common adverse reactions (affecting up to 1 in 10 individuals) frequently involve the Nervous System and Gastrointestinal System, including somnolence (drowsiness), headache, fatigue, and dry mouth. Less frequent effects are documented across various systems, with pruritus (itching) and diarrhea listed as uncommon.


Serious Reactions and Regulatory Constraints

Rare and Very Rare adverse reactions include severe systemic events. Documented serious adverse reactions include anaphylactic shock, angioneurotic oedema (rapid swelling), convulsions, and abnormal hepatic function (liver enzyme increase). These represent the most significant potential safety concerns listed in regulatory labeling.


Special Populations and Limitations

  • Population-Specific Constraint: The medicine is contraindicated in patients diagnosed with severe end-stage renal disease (creatinine clearance less than 10 mL/min). Dose adjustment is required for individuals with moderate renal impairment.
  • Safety Precaution: Caution is advised for patients with risk factors for urinary retention or those with a history of convulsions, due to the documented potential for these events.
  • Exposure-Related Pattern: Regulatory sources note that severe pruritus has been reported upon discontinuation following long-term, continuous daily use.

This official information structures the understanding of potential risk by placing common, generally non-serious effects like drowsiness in the highest frequency category, while formally defining the boundaries and scope of the drug’s regulatory risk profile through explicit constraints for severe organ impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is required upon suspected or confirmed overdose of Li Min (Cetirizine Hydrochloride), and regulators mandate contacting a poison control center immediately. Management of overexposure is strictly symptomatic and supportive treatment, as no specific antidote is known for cetirizine.

Overdose manifestations are primarily characterized by central nervous system (CNS) effects. Documented signs include significant drowsiness (somnolence, fatigue, tiredness) and may escalate to confusion or stupor in severe cases. Other formally described clinical signs are tachycardia (fast heart rate), tremor, headache, diarrhea, malaise, and urinary retention.

Overdose Context
Population-Specific Notes Overdose in adults typically presents with drowsiness, while children may exhibit agitation or restlessness before the onset of sedation.
Management Procedures Medical professionals may consider gastric lavage shortly after acute ingestion, and close medical observation may be necessary. The substance is not effectively removed by dialysis through standard procedures.

These official regulatory statements define the necessary emergency actions and the constraints on medical intervention, underscoring the requirement to seek urgent professional guidance in all overdose scenarios.

Therapeutic Uses of Li Min

What Li Min Treats: Main Uses and Benefits

Li Min is used to provide symptomatic relief in clinical settings marked by allergic rhinitis and chronic urticaria, addressing symptoms that create noticeable physiological strain during allergic episodes. This includes managing common allergic conditions like seasonal and perennial allergic rhinitis and dermal symptoms of chronic idiopathic urticaria and generalized allergic pruritus.

The medication is utilized to relieve symptoms such as sneezing, runny nose, itchy, red, watery eyes, and itchy nose or throat due to allergies. This therapeutic domain may be part of symptomatic management for symptom clusters that may appear suddenly or intensify over time when exposed to common allergens. By easing this symptomatic discomfort, the medication supports patients during difficult episodes and assists with maintaining functional stability.

“It is commonly applied in scenarios where additional management of discomfort is required to support the patient during difficult episodes.”

Brief Listing of Indications: The medication is used for managing conditions associated with the symptom categories of allergic rhinitis and chronic urticaria (hives) and allergic pruritus (itching).

Quick Fact: Use in Dermal Symptoms The medication is relevant in conditions characterized by periods of heightened symptoms, where the intense itching and development of raised welts interfere with daily functioning, and provides support that may help ease the overall symptom burden.

Regulatory References

  1. Cetirizine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official eligibility profile for Li Min (Cetirizine Hydrochloride) is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated populations.

Contraindications and Restrictions

Classification Population Status
Contraindication Severe renal impairment (CrCL < 10 mL/min); Hypersensitivity to cetirizine, hydroxyzine, or piperazine derivatives. Must Not Use
Age Restriction Tablet formulation for children under 6 years. Not Recommended

Conditional Use and Eligibility

Use is formally established for adults and adolescents and is approved for children as young as six months (formulation dependent). Conditional use is required for individuals with moderate renal impairment (CrCL 10 to 79 mL/min) or combined hepatic and renal impairment. Use in these groups requires specific regulatory management.

Official labeling also recommends caution for patients at risk of convulsions or those with predisposing factors for urinary retention. For pregnancy, use should be reserved only when clearly necessary. The drug is excreted into human milk, resulting in a not recommended status for use during lactation in some regulatory jurisdictions.

What should I know about interactions with other medicines?

The official interaction profile for Li Min (Cetirizine Hydrochloride) is defined by its minimal metabolic activity and its potential for functional additive effects on the central nervous system (CNS). All interactions are based strictly on regulatory document findings.

Interaction scope

Category Description / Entity
Medicinal product categories with documented interactions Central Nervous System (CNS) Depressants (e.g., sedatives, tranquilizers, opioids).
Specific interacting medicines (if explicitly listed) Theophylline (at a daily dose of 400 mg). Alcohol (Ethanol).
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic enhancement (additive CNS depression). Pharmacokinetic alteration (reduced clearance of Cetirizine).
Timing-based interaction rules (if applicable) None explicitly mandated in regulatory labeling for separation of doses.

Interaction classifications (high-level)

Classification Description
Interaction severity classification No combinations are classified as Contraindicated based solely on drug-drug interaction risk. Interactions with CNS Depressants and Alcohol are warnings based on Additive Effects.
Interaction-context constraints Food consumption delays the time to reach peak plasma concentration (Tmax) but does not reduce the total extent of absorption (AUC).

Resulting interaction structure

Official interaction statements:

  • Co-administration with Alcohol or other CNS Depressants may result in an additional reduction in alertness and additional impairment of CNS performance.
  • A small decrease in Cetirizine clearance (16%) was observed in regulatory studies when co-administered with a specific dose of Theophylline.
  • No clinically significant pharmacokinetic interactions were found with Erythromycin or Ketoconazole, reflecting the medicine's minimal interaction with major metabolic pathways.

The regulatory interaction structure for Li Min is primarily defined by warnings against pharmacodynamic enhancement due to concurrent use with CNS depressants and alcohol, increasing the risk of central impairment. The medicine exhibits a generally neutral pharmacokinetic profile, with only a minor, documented reduction in clearance when co-administered with Theophylline.

Mechanism of Action

Enzyme Inhibition: Reducing Signal Amplification

The Li Min ion ( Li^+) primarily acts as an inhibitor of the enzyme Inositol Monophosphatase ( IMPase), a key component of the Phosphatidylinositol (PI) signaling pathway. This inhibition limits the recycling of essential signaling molecules in the cell. The subsequent cellular consequence is a reduction of signal amplification within affected neurons, influencing their net excitability.


Modulating Neuroplasticity and Cell Survival

Li^+ also modulates processes associated with neuronal survival by inhibiting Glycogen Synthase Kinase 3 beta ( GSK-3beta). This promotes the nuclear expression of neurotrophic factors and anti-apoptotic proteins. This activity is associated with changes in neuronal structure and function, including modifications in gray matter volume over time.


Ion Competition and Neurotransmitter Balance

As a monovalent ion, Li^+ influences electrochemical gradients by competing with sodium ( Na^+) for transport mechanisms across cell membranes. This modifies the activity ratio between excitatory signals (like glutamate) and inhibitory signals, further influencing net neuronal excitability. Peripherally, this competition is also responsible for the drug's effect on renal fluid and electrolyte balance.

Dosage and Administration Information

Li Min is administered through two approved routes: oral (available as tablets, capsules, and solutions) and intravenous (IV) injection. The IV route, supplied as a single-use injectable solution, is intended for professional use in acute care settings and is administered as an intravenous push over a period of 1 to 2 minutes.


Standard Dosing and Frequency

The fundamental regimen for Li Min is a fixed dose taken once every 24 hours. For adults and adolescents 12 years of age and older, the oral dose is typically 5 mg or 10 mg once daily, and the daily dose must not exceed 10 mg. Oral forms may be taken with or without food, and liquid solutions require accurate measurement using the enclosed dosing cup.

Population-Specific Use

Dose adjustments are required based on physiological status. The oral dose is reduced to 5 mg once daily for older adults (65 years and older) and for patients with moderately decreased renal function (creatinine clearance le 50 mL/min). If a regular dose is missed, instructions advise taking it as soon as possible, then resuming the normal once-daily schedule, while explicitly prohibiting taking two doses to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Li Min

Evidence for use in Allergic Rhinitis (Seasonal and Perennial)

The research landscape for Li Min is largely based on randomized controlled trials (RCTs) and subsequent meta-analyses. These short-term studies examined symptoms measured over defined time intervals in people with seasonal and perennial allergic rhinitis. These trials were applied in research contexts involving fluctuating or unstable symptoms related to runny nose, sneezing, and itchy/watery eyes. The studies assessed subjective metrics like the Total Nasal Symptom Score (TNSS), a metric used to capture symptom intensity.

Data show patterns related to measurements in the objective and subjective scores for nasal and ocular symptoms when comparing the compound's use to placebo over short periods. Research highlights changes measured during the study period, noting that patient-reported outcomes describing perceived discomfort were observed alongside symptom score changes.


Evidence for use in Chronic Urticaria (Hives and Itching)

The compound was evaluated in patients with chronic urticaria (hives), a condition characterized by fluctuating or episodic manifestations. This evidence is built upon Randomized Controlled Trials (RCTs) that often compared the compound to a placebo over brief observation periods, monitoring outcomes linked to inflammatory states, specifically focusing on Wheal Severity Scores and Pruritus Severity Scores (outcomes related to physical discomfort).

Trials reported patterns related to the severity scores for both weals and pruritus in the observed populations over defined time intervals. However, evidence is limited when considering patients whose symptoms were described as persistently active despite standard treatment. Smaller trials were conducted for these particular subgroups, and these findings help contextualize how patients reported their experience when treated with doses exceeding the initially studied regimen.


What is Still Uncertain in the Research Landscape

Long-term effects are not fully established regarding sustained symptom scores beyond six months; follow-up durations were limited in most rigorous studies. Comparative evidence is lacking for specific patient subgroups, particularly older adults and those with multiple pre-existing medical conditions, meaning that findings describe group patterns but not individual predictions for these smaller groups.

Key Studies & References

  1. Cetirizine: MedlinePlus Drug Information
  2. Chronic urticaria: off-label doses of cetirizine | NICE Evidence Summary

Frequently Asked Questions (FAQ)

Common questions about Li Min (FAQ)


Q: Is Li Min an antibiotic or something else?

A: Li Min is classified as a Second-Generation Antihistamine, according to official product information. This means it works by blocking the action of histamine, a natural chemical in the body that causes allergy symptoms. It is used for allergy relief and is not an antibiotic.


Q: Are there any common foods or drinks that should be avoided when using Li Min?

A: Official warnings caution that the use of Li Min with alcohol may lead to an additional reduction in alertness and impairment of performance. Regarding food, regulatory studies show that taking the medication with food can delay the time it takes to reach maximum concentration, but the overall amount of medication absorbed by the body is not reduced.


Q: Is Li Min known to be safe for older adults?

A: Official regulatory guidelines mandate that the dose must be adjusted (reduced) for older adults, generally defined as 65 years and older. This requirement for dose adjustment is a regulatory precaution based on typical changes in metabolism and elimination observed in this population.


Q: Is Li Min a controlled substance?

A: According to official regulatory data, Li Min is not classified as a Controlled Substance in the United States.


Q: Can Li Min cause long-term side effects?

A: Regulatory warnings indicate that severe itching ( pruritus) has been reported upon discontinuation of the medicine after long-term, continuous daily use. Regulatory warnings indicate that studies on continuous use beyond certain timeframes are limited.


Q: Is it safe to drive while using Li Min?

A: Official labeling contains a caution regarding the performance of activities that require complete mental alertness, such as driving or operating machinery. This is because the drug is known to cause somnolence (drowsiness) and may potentially impair performance or alertness.


Q: How long can a person usually stay on Li Min?

A: The medication is approved for chronic conditions, such as perennial allergic rhinitis and chronic urticaria. Regulatory safety communications often mention use daily for 'at least a few months and often years' in their descriptions of usage patterns.


Q: Does taking Li Min impact fertility?

A: Based on non-clinical animal studies, there was no reported evidence of a direct adverse effect on fertility. There are no definitive human studies to suggest the medication reduces fertility in men or women.


Q: Are weight changes a known side effect of Li Min?

A: According to official regulatory documentation, an increase in weight is listed as an uncommon reported adverse effect.


Q: Can Li Min interact with common over-the-counter pain relievers?

A: Regulatory studies suggest that the medicine has minimal involvement with major metabolic pathways. The official warnings about interactions focus specifically on Central Nervous System (CNS) depressants, alcohol, and the drug theophylline.


Q: What should I do if a side effect of Li Min seems severe?

A: The regulatory label lists rare but serious adverse reactions, which include anaphylactic shock, rapid swelling ( angioneurotic oedema), and changes in liver function. Serious adverse reactions are defined in regulatory documents as those that warrant immediate attention from a healthcare professional.


Q: Is Li Min considered a high-risk medication during pregnancy?

A: The official advice is that use during pregnancy should be reserved only when clearly necessary. Regulatory data indicate the medication is not associated with increased risk of malformation in the first trimester when compared to placebo.


Q: How does the effectiveness of Li Min compare to placebo in studies?

A: In clinical trials, the medication demonstrated strong antihistaminic activity compared to placebo. It effectively inhibited the skin reactions (wheal and flare) caused by injected histamine, which provides regulatory evidence of its mechanism.


Q: How long after stopping Li Min does it stay in the system?

A: Official pharmacokinetic data indicates that the average elimination half-life is approximately 8.3 hours in adults. This timeframe can be longer for older adults or individuals with reduced kidney function.


Q: Is it true that Li Min can cause confusion in some patients?

A: Yes, confusion is listed in regulatory documents as a potential adverse effect that has been reported during post-marketing use.


Q: Is there a generic version of Li Min?

A: Yes, the active ingredient in Li Min, Cetirizine Hydrochloride, is widely available as a generic medication.


Q: Is Li Min known to cause issues with blood pressure?

A: Regulatory documents list both abnormally high blood pressure ( hypertension) and abnormally low blood pressure ( hypotension) as rare or very rare reported adverse effects.


Q: Can I use Li Min if I have a history of heart problems?

A: Regulatory studies found no significant issues with QTc prolongation, even when the medication was tested at high doses. Regulatory findings show no significant QTc prolongation.


Q: Is Li Min approved by the FDA?

A: Yes, the active ingredient Cetirizine Hydrochloride is an FDA-approved medication and is supported by labeling from the U.S. Food and Drug Administration and other global regulatory bodies.


Q: Is there an official patient information leaflet for Li Min?

A: Yes, government regulations require that all prescription and over-the-counter medications are accompanied by official labeling. This includes documents like a Patient Information Leaflet (PIL) or a Drug Facts Label.


Q: Is there a risk of becoming dependent on Li Min?

A: The drug is not classified as a Controlled Substance in the US.


Q: Do I need special monitoring tests (like bloodwork) while on Li Min?

A: Routine blood work is not generally mandated for this medication. Caution and management are described in official labeling for patients with existing liver ( hepatic) or kidney ( renal) impairment.


Q: What are the most commonly reported reasons for stopping Li Min treatment?

A: The most common adverse reactions reported in clinical trials were somnolence (drowsiness), headache, and fatigue. These effects are the most frequent reported adverse reactions, which often correlate with discontinuation in clinical trials.


Q: Is Li Min used to treat conditions other than its main approved use?

A: Official regulatory documents define the approved uses as seasonal and perennial allergic rhinitis and chronic urticaria (hives).


Q: How is Li Min eliminated from the body?

A: The medication is largely excreted unchanged through the urine, accounting for about 50% of an administered dose. It undergoes minimal metabolism by the liver before elimination.


Q: What happens if Li Min is taken by someone who shouldn't use it?

A: The medication is Contraindicated for patients with severe end-stage renal disease and those with a known hypersensitivity to the drug or its components. Regulatory documents establish that use in contraindicated populations is associated with a higher risk of adverse health outcomes.


Q: Is Li Min affected by grapefruit juice?

A: Official regulatory documents do not list an interaction with grapefruit juice. This is consistent with the medication's minimal involvement with CYP450 liver enzymes.


Q: What is the typical timeframe for seeing the full benefit of Li Min?

A: The medication is considered fast-acting, with the onset of activity occurring within 20 to 60 minutes after taking a single dose. The effect typically persists for at least 24 hours.


Q: Can I split or crush the Li Min tablet?

A: Official regulatory guidance on dosage and administration advises that certain tablets, particularly fixed-combination products, should not be broken or chewed. The label does not contain specific instructions for splitting or crushing the standard single-ingredient tablet.

How should Li Min be stored and disposed of?

Storage and Protection Requirements

Li Min (Cetirizine Hydrochloride) must be stored at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F), to maintain stability. The medicine should be kept away from excessive heat, moisture, and direct light, and it is prohibited to freeze the product. The container must be kept tightly closed and maintained in its original packaging. Liquid formulations must be used within 6 months after opening.

Safety and Disposal

For safety, the product must be stored out of the sight and reach of children. Unused or expired Li Min must not be disposed of via household waste or wastewater and must be handled in accordance with local pharmaceutical disposal requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Li Min found in:

A-Z Index: